New Zealand actor Sam Neill, known for his role as Dr. Alan Grant in Jurassic Park, has died on July 13, 2026.
Sam Neill, the celebrated New Zealand actor known for Sleeping Dogs, Jurassic Park, and Peaky Blinders, has sadly died on July 13, 2026, at age 78.
Neill died in Sydney, Australia, and no cause of death has been given at this time, though Neill had recently announced he was cancer-free following treatment for angioimmunoblastic T-cell lymphoma.
According to the statement posted on Neill’s social media page, his death was “sudden and unexpected,” and he was “surrounded by family.” His family then went on to express their gratitude to St. Vincent’s Private Hospital for their incredible care.
Sam Neill’s impressive career spanned over five decades and 150 credits, cementing himself as one of Hollywood’s most recognizable presences. For many audiences, he will be remembered for his role as Dr. Alan Grant, the reluctant paleontologist in Steven Spielberg’s 1993 film Jurassic Park, later returning to the role in Jurassic Park III and Jurassic Park Dominion.
Read the full article on GameRant
This article originally appeared on GameRant and is republished here with permission.
Read the full article here
25 Comments
Silver leverage is strong here; beta cuts both ways though.
Good point. Watching costs and grades closely.
Interesting update on Jurassic Park Actor Sam Neill Has Died At 78. Curious how the grades will trend next quarter.
Silver leverage is strong here; beta cuts both ways though.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Nice to see insider buying—usually a good signal in this space.
Good point. Watching costs and grades closely.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
I like the balance sheet here—less leverage than peers.
Exploration results look promising, but permitting will be the key risk.
Good point. Watching costs and grades closely.
If AISC keeps dropping, this becomes investable for me.
Good point. Watching costs and grades closely.
If AISC keeps dropping, this becomes investable for me.
If AISC keeps dropping, this becomes investable for me.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Silver leverage is strong here; beta cuts both ways though.
Good point. Watching costs and grades closely.